These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 17940447)

  • 1. Androgen deprivation therapy for prostate cancer: new concepts and concerns.
    Smith MR
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):247-54. PubMed ID: 17940447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
    N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.
    Saylor PJ; Kaufman DS; Michaelson MD; Lee RJ; Smith MR
    J Urol; 2010 Jun; 183(6):2200-5. PubMed ID: 20399451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.
    Smith MR
    Cancer Metastasis Rev; 2002; 21(2):159-66. PubMed ID: 12465755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
    Smith MR; Fallon MA; Goode MJ
    Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy Insight: osteoporosis during hormone therapy for prostate cancer.
    Smith MR
    Nat Clin Pract Urol; 2005 Dec; 2(12):608-15; quiz 628. PubMed ID: 16474548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of fracture after androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
    N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of treatment-related osteoporosis in men with prostate cancer.
    Smith MR
    Cancer Treat Rev; 2003 Jun; 29(3):211-8. PubMed ID: 12787715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
    J Urol; 2010 Oct; 184(4):1316-21. PubMed ID: 20723926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.